» Articles » PMID: 17291377

The Burden of Parvovirus B19 Infection in Women of Childbearing Age in England and Wales

Overview
Date 2007 Feb 13
PMID 17291377
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

A serological survey has been used to investigate the epidemiology of parvovirus B19 infection in England and Wales. A total of 2835 sera representing the complete age range were selected from a convenience collection obtained in 1996 that reflects the general population and screened for parvovirus B19-specific IgG. Antibody prevalence rose nonlinearly with age from 21% in those aged 1-4 years to >75% in adults aged > or = 45 years. Force-of-infection estimates were similar to those previously made in 1991, being highest in those aged <15 years. There was no association between evidence of previous infection and sex or region. Quantitatively strongest antibody responses were found in those aged 15-34 years and IgG levels in females were 28.5% higher than those found in males (P=0.004, 95% CI 8.2-52.6). Applying the upper 95% confidence interval for the force of infection to maternity estimates for England and Wales in 1996, parvovirus infection in pregnancy was estimated to occur on average in up to 1 in every 512 pregnancies each year. This represents 1257 maternal infections, causing up to an estimated 59 fetal deaths and 11 cases of hydrops fetalis annually. An analysis of all available laboratory-confirmed parvovirus infections found a mean of 944 infections per year in women aged 15-44 years highlighting a need for enhanced surveillance of maternal parvovirus B19 infection in England and Wales, including information on both pregnancy and outcome of pregnancy.

Citing Articles

Genotypic Characterization of Human Parvovirus B19 Circulating in the 2024 Outbreak in Tuscany, Italy.

Beligni G, Alessandri G, Cusi M Pathogens. 2025; 14(2).

PMID: 40005498 PMC: 11858505. DOI: 10.3390/pathogens14020121.


Using Catalytic Models to Interpret Age-Stratified Lyme Borreliosis Seroprevalence Data: Can This Approach Help Provide Insight into the Full Extent of Human Infection Occurring at the Population Level?.

Vyse A, Colby E Microorganisms. 2025; 12(12.

PMID: 39770840 PMC: 11678136. DOI: 10.3390/microorganisms12122638.


Efficient Neutralizing Antibodies Induction by Human Parvovirus B19 Epitope-Presenting Protein Nanoparticles.

Kimura S, Suzuki H, Hatakeyama Y, Noguchi T, Ii K, Nakamura K Microbiol Immunol. 2024; 69(1):35-42.

PMID: 39545388 PMC: 11701389. DOI: 10.1111/1348-0421.13182.


Changing epidemiology of parvovirus B19 in the Netherlands since 1990, including its re-emergence after the COVID-19 pandemic.

Russcher A, van Boven M, Beninca E, Verweij E, Molenaar-de Backer M, Zaaijer H Sci Rep. 2024; 14(1):9630.

PMID: 38671058 PMC: 11053065. DOI: 10.1038/s41598-024-59582-7.


Parvovirus B19 in Croatia: A Large-Scale Seroprevalence Study.

Vilibic-cavlek T, Tabain I, Kolaric B, Mihulja K, Blazevic L, Bogdanic M Medicina (Kaunas). 2021; 57(11).

PMID: 34833497 PMC: 8617724. DOI: 10.3390/medicina57111279.


References
1.
Osborne K, Gay N, Hesketh L, Morgan-Capner P, Miller E . Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol. 2000; 29(2):362-8. DOI: 10.1093/ije/29.2.362. View

2.
Vyse A, Gay N, Hesketh L, Pebody R, Morgan-Capner P, Miller E . Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century. Epidemiol Infect. 2006; 134(6):1303-12. PMC: 2870519. DOI: 10.1017/S0950268806006340. View

3.
Kelly H, Riddell M, Gidding H, Nolan T, Gilbert G . A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine. 2002; 20(25-26):3130-6. DOI: 10.1016/s0264-410x(02)00255-4. View

4.
Gay N, Vyse A, Enquselassie F, Nigatu W, Nokes D . Improving sensitivity of oral fluid testing in IgG prevalence studies: application of mixture models to a rubella antibody survey. Epidemiol Infect. 2003; 130(2):285-91. PMC: 2869964. DOI: 10.1017/s0950268802008051. View

5.
Blumberg B . Sex differences in response to hepatitis B virus. I. History. Arthritis Rheum. 1979; 22(11):1261-6. DOI: 10.1002/art.1780221114. View